Sodium Edecrin (ethacrynate sodium)

Dosage of ethacrynate sodium is expressed in terms of ethacrynic acid. Dosage must be adjusted according to the patient's requirements and response. The smallest dose required to produce a gradual weight loss of 0.45-0.9 kg (1-2 pounds) daily should be used. Some clinicians have suggested that the drug not be given for more than 2 days consecutively until the patient's responsiveness is known. If ethacrynic acid is added to the regimen of a patient stabilized on a potent hypotensive agent, the dosage of the hypotensive agent may require reduction to avoid severe hypotension.

For the management of fluid retention (e.g., edema) associated with heart failure, experts state that diuretics should be administered at a dosage sufficient to achieve optimal volume status and relieve congestion without inducing an excessively rapid reduction in intravascular volume, which could result in hypotension, renal dysfunction, or both.

No dosing information is available for this tab.

No dosing information is available for this tab.

No dosing information is available for this tab.

There is no enhanced messaging for this drug.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

There is no enhanced messaging for this drug.

There are no contraindication contraindications for this drug.

There are no severe contraindications for this drug.

There are no moderate contraindications for this drug.

There is no enhanced messaging for this drug.

There are no severe adverse reactions for this drug.

There are no less severe adverse reactions for this drug.

No enhanced messaging available.

No enhanced messaging available.

Reproduction studies in dogs and rats receiving oral ethacrynic acid dosages of 5 and 20 mg/kg daily (approximately 2.5 or 10 times the daily human dosage), respectively, did not reveal evidence of interference with pregnancy or with growth and development of the offspring. In rats receiving 100 mg/kg (50 times the human dose), mean fetal body weight was reduced, but no effects on mortality or postnatal development or functional or morphologic abnormalities were observed. Reproduction studies in mice and rabbits receiving ethacrynic acid at dosages up to 50 times the recommended human dosage have not revealed evidence of external abnormalities of the fetus. Safety and efficacy of ethacrynic acid in toxemia of pregnancy have not been established. Because there are no adequate and well-controlled studies to date using ethacrynic acid in pregnant women and animal studies are not always predictive of human response, the drug should be used during pregnancy only when clearly needed. Polyhydramnios (suggesting increased fetal urine production) and neonatal diuresis and nephrolithiasis occurred following chronic maternal ethacrynic acid therapy (50 mg twice daily orally) during pregnancy.

It is not known whether ethacrynic acid is distributed into milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions to ethacrynic acid in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the woman.

No enhanced messaging available.